How Procurement and QA Review a Peptide API CMC Dossier Before Sourcing

When procurement and QA teams ask how to review a peptide API CMC dossier before sourcing, the answer starts with scope. The CMC section describes chemistry, manufacturing, and controls for the active ingredient. Buyers should request a table of contents first, confirm which sections are complete, and note which parts are placeholders. A dossier that is transparent about gaps is easier to assess than one that appears complete but lacks traceable references. Treat the dossier as a working document to be discussed, not a marketing artifact.

Begin with the manufacturing process description. Review the route of synthesis, starting materials, protecting group strategy, coupling and deprotection steps, cleavage, and purification. Check whether critical process parameters are identified and whether in-process controls are described for each stage. Procurement does not need to judge the chemistry, but QA should confirm that the described process matches the material actually supplied. Ask how process changes are documented and whether historical batch data support the current description.

Next, examine characterization and structure elucidation. A credible dossier explains how the peptide sequence, molecular weight, and modifications were confirmed. Look for descriptions of the analytical techniques used and how results are interpreted. QA reviewers should check that the characterization package aligns with the certificate of analysis for supplied lots. Where the peptide contains non-natural amino acids, conjugates, or disulfide bonds, confirm that the dossier addresses those features explicitly rather than relying on generic statements.

Impurity discussion deserves close reading. The dossier should describe identified and unidentified impurities, how they were assigned, and the rationale for specifications. QA should compare the impurity profile described in the dossier with the release testing performed on commercial lots. Procurement can use this section to ask suppliers how they handle out-of-specification impurity results and whether investigations are shared with customers. Do not accept a dossier that lists specifications without explaining how they were derived.

Specifications and analytical methods form the core of the review. Confirm that each specification has a corresponding validated method, and check whether method validation summaries are included or referenced. QA should verify that the methods described are the same ones used for release and stability testing. Ask about reference standards, system suitability criteria, and how method transfers would be handled if the buyer performs confirmatory testing. Gaps here often surface later during audits or regulatory review.